Tuesday, April 16, 2019 11:23:31 PM
flipper44,
I think that Dr. Linda Liau and UCLA have a pretty good idea of when top line results will be released and if you can get her to comment you would probably have a reliable answer. NWBO seems to want as many ducks in a row as possible before they say anything. I think the journal snafu taught them what they are up against. They won't say anything until they have what they need in their hands. No more taking anyone's word for anything. Their experiences with Mr. Woodford, Ms Katherine Wolf, perhaps their former DMC chair, perhaps the former head of FDA, perhaps a strained relationship between the ex CEO of Cenkos and director Dr. Navid Malik and the journal issue I am sure have taught them some valuable lessons. Perhaps NWBO is about ready to teach some lessons of their own and they want the lesson plan very well organized and on their timeline instead of someone else's. Best wishes.
I think that Dr. Linda Liau and UCLA have a pretty good idea of when top line results will be released and if you can get her to comment you would probably have a reliable answer. NWBO seems to want as many ducks in a row as possible before they say anything. I think the journal snafu taught them what they are up against. They won't say anything until they have what they need in their hands. No more taking anyone's word for anything. Their experiences with Mr. Woodford, Ms Katherine Wolf, perhaps their former DMC chair, perhaps the former head of FDA, perhaps a strained relationship between the ex CEO of Cenkos and director Dr. Navid Malik and the journal issue I am sure have taught them some valuable lessons. Perhaps NWBO is about ready to teach some lessons of their own and they want the lesson plan very well organized and on their timeline instead of someone else's. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
